COMUNICADO: Eucure Biopharma anuncia resultados de fase I para terapia anti-CTLA-4 (2)
22 de marzo de 2021 (15:31 h.)
Logo -- https://mma.prnewswire.com/media/1358305/Biocytogen_Logo.jpg [https://c212.net/c/link/?t=0&l=es&o=3102059-1&h=3607117936&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3102059-1%26h%3D2547310776%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1358305%252FBiocytogen_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1358305%252FBiocytogen_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1358305%2FBiocytogen_Logo.jpg]